77.4%
SARS-COV-2 mRNA vaccinesNSCLCmetastatic melanomaStage IV non-small cell lung cancerStage IV melanomaMD Anderson Cancer Center
…an TPS (14% vs 8.9%, p=0.029) in the tissue agnosticConclusions SARS-COV-2 mRNA vaccines stimulate expansion of tumor-reactive T cells in preclinical mo…